TWST Short Interest
Twist Bioscience Corporation (TWST) operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry, with a market capitalization near $3.39B, listed on NASDAQ, employing roughly 923 people, carrying a beta of 2.23 to the broader market. Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. Led by Emily Marine Leproust, public since 2018-10-31.
Short interest is the total number of shares currently sold short and not yet covered, reported bi-monthly by FINRA. Days to cover (short interest divided by average daily volume) indicates how long it would take short sellers to close positions, with higher values signaling greater squeeze potential.
- Settlement Date
- 2026-04-30
- Short Interest
- 13.9M
- Previous Short Interest
- 14.5M
- Change
- -4.18%
- Days to Cover
- 10.46
- Avg Daily Volume
- 1.3M
- Avg Days to Cover (24 reports)
- 9.32
Showing 24 bi-monthly FINRA short interest reports for Twist Bioscience Corporation.
Learn how short interest is reported and how to read the data →
Frequently asked TWST short interest questions
- What is the current TWST short interest?
- As of the Apr 30, 2026 settlement, Twist Bioscience Corporation (TWST) short interest is 13.9M shares, a -4.18% change from the prior period. FINRA publishes short interest twice monthly on the 15th and last business day of each month under Rule 4560.
- What is the TWST days-to-cover ratio?
- Days-to-cover is 10.46, calculated as short interest divided by average daily volume. It estimates how many trading days closing all short positions would consume given typical liquidity. Values above 5 days are commonly cited as elevated; values above 10 days are squeeze-relevant.
- How does TWST short interest affect options pricing?
- High short interest changes options pricing through three mechanics: borrow-rebate effects (synthetic long stock trades below frictionless put-call parity by approximately the borrow rebate when shares are hard-to-borrow), gamma-squeeze setup risk (if dealers are short gamma against retail call buying, dealer hedge flow can amplify upward moves), and elevated event-vol pricing on names with squeeze potential. See the canonical short-interest documentation for the full mechanism.